VX-478 non-peptide HIV protease inhibitor data

Partner Burroughs Wellcome presented preclinical data showing an acceptable safety profile and synergism with AZT and ddI.

VRTX (Cambridge, Mass.) said the agent has a 90 percent inhibitory concentration (IC90) of 40 nM against the HTLV IIIb isolate in CEM cells, and also is highly potent against a variety of laboratory strains and primary isolates in various human cells. It had low cytotoxicity and high selectivity for the viral enzyme compared to human aspartic acid proteases. ...